Strahlentherapie und Onkologie

, Volume 192, Issue 1, pp 1–7 | Cite as

Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery

  • Gerd FastnerEmail author
  • Cornelia Hauser-Kronberger
  • Angelika Moder
  • Roland Reitsamer
  • Franz Zehentmayr
  • Peter Kopp
  • Christoph Fussl
  • Thorsten Fischer
  • Heinrich Deutschmann
  • Felix Sedlmayer
Original Article



The purpose of this work was to retrospectively evaluate survival and local control rates of triple-negative breast cancer subtypes classified as five marker negative (5NP) and core basal (CB), respectively, after breast-conserving surgery and intraoperative boost radiotherapy with electrons (IOERT) followed by whole breast irradiation.

Methods and materials

A total of 71 patients with triple-negative breast cancer were enrolled, who were treated with lumpectomy, axillary lymph node dissection, and IOERT with 9.6 Gy (median Dmax) followed by normofractionated whole breast irradiation to median total doses of 54 Gy. Chemotherapy was applied in a neoadjuvant (12 %), adjuvant (75 %), or combinational setting (7 %).


After a median follow-up of 97 months (range 4–170 months), 5 in-breast recurrences were detected (7.0 %). For all patients, 8-year actuarial rates for local control, metastases-free survival, disease-specific survival, and overall survival amounted to 89, 75, 80, and 69 %, respectively. All local recurrences occurred in grade 3 (G3) tumors irrespective of their specific immunohistochemical phenotype; thus, the local control rate for grades 1/2 (G1/2) was 100 % for both 5NP and CB, while for G3 it was 88 % for 5NP and 90 % for CB (p = 0.65 and 0.82, respectively, n.s.). For disease-specific survival, only the difference of the best-prognosis group 5-NP/G3 vs. the worst-prognosis cohort CB/G1/2 was statistically significant: 90 % vs. 54 % (p = 0.03).


Boost-IOERT provides acceptable long-term in-breast control in triple negative breast cancer. The best subgroup in terms of disease-specific survival was represented by 5NP in combination with tumor grading G3.


Triple-negative breast neoplasms Intraoperative radiotherapy Breast conserving surgery Electrons Recurrence 

Überlebens- und Lokalkontrollraten bei triple-negativen Mammakarzinomen nach brusterhaltender Operation und IOERT als vorgezogenem Tumorbettboost



Ziel der Studie war es, im Rahmen einer retrospektiven Analyse Überlebens- und Lokalkontrollraten bei triple-negativen Mammakarzinomen zu untersuchen. Die Tumoren waren in 5NP(5-Marker-negative)- und CB(core basal)-Subtypen klassifiziert und die Patientinnen hatten nach brusterhaltender Operation und intraoperativem Elektronenboost (IOERT) eine Ganzbrustbestrahlung erhalten.

Material und Methoden

Insgesamt 71 Patientinnen mit triple-negativem Mammakarzinom erhielten während einer Lumpektomie und axillärer Lymphknotendissektion eine IOERT (med Dmax 9,6 Gy ) und danach eine Ganzbrustbestrahlung in konventioneller Fraktionierung (mediane Gesamtdosis 54 Gy). Eine Chemotherapie wurde in neoadjuvanter (12 %), adjuvanter (75 %) oder kombinierter (7 %) Sequenz durchgeführt.


Nach einer medianen Follow-up-Phase von 97 Monaten (Bereich 4–170) wurden 5 ipsilaterale In-Brust-Rezidive festgestellt (7%). Die aktuarischen Achtjahresraten aller Patientinnen für lokale Kontrolle bzw. metastasenfreies, krankheitsspezifisches und Gesamtüberleben lagen entsprechend bei 89, 75, 80 und 69 %. Unabhängig vom immunhistochemischen Phänotyp traten alle Lokalrezidive bei Tumoren mit niedrigem Differenzierungsgrad G3 auf [Lokalkontrollen: G1/2 (CB und 5NP) 100 % vs. G3 88 % (5NP) und 90 % (CB), p = 0,65 bzw. 0,82; n.s.]. Bezüglich des krankheitsspezifischen Überlebens zeigte der Vergleich zwischen der Subgruppe mit der besten Prognose 5NP/G3 und der mit der schlechtesten Prognose CB/G1/2 statistische Signifikanz: 90 vs. 54 % (p = 0,03).


Bei konservativ operierten triple-negativen Mammakarzinomen erzielt die IOERT als Boostmodalität vor einer Ganzbrustbestrahlung auch langfristig akzeptable Lokalkontrollraten. Die Kombination eines 5NP-Subtyps mit dem Tumordifferenzierungsgrad G3 zeigt einen signifikanten Vorteil im krankheitsspezifischen Überleben.


Triple-negative Mammaneoplasien Intraoperative Strahlentherapie Brusterhaltende Operation Elektronen Rezidiv 


Compliance with ethical guidelines

Conflict of interest

G. Fastner, C. Hauser-Kronberger, A. Moder, R. Reitsamer, F. Zehentmayr, P. Kopp, C. Fussl, T. Fischer, H. Deutschmann, and F. Sedlmayer state that there are no conflicts of interest.

The accompanying manuscript does not include studies on humans or animals.


  1. 1.
    Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Lowery AJ, Kell MR, Glynn RW et al (2012) Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 133:831–841PubMedCrossRefGoogle Scholar
  3. 3.
    Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Perou CM (2010) Molecular stratification of triple-negative breast cancers. Oncologist 15:39–48PubMedCrossRefGoogle Scholar
  5. 5.
    Peddi PF, Ellis MJ, Ma C (2012) Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012:217185. doi:10.1155/2012/217185PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376PubMedCrossRefGoogle Scholar
  7. 7.
    Cho EY, Chang MH, Choi YL et al (2011) Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemother Pharmacol 68:753–761PubMedCrossRefGoogle Scholar
  8. 8.
    Uhm JE, Park YH, Yi SY et al (2009) Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 124:1457–1462PubMedCrossRefGoogle Scholar
  9. 9.
    Sedlmayer F, Sautter-Bihl ML, Budach W et al (2013) DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol 189:825–833PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Bartelink H, Maingon P, Poortmans P et al (2015) Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16:47–56PubMedCrossRefGoogle Scholar
  11. 11.
    Reitsamer R, Sedlmayer F, Kopp M et al (2006) The Salzburg concept of intraoperative radiotherapy for breast cancer: results and considerations. Int J Cancer 118:2882–2887PubMedCrossRefGoogle Scholar
  12. 12.
    Sedlmayer F, Fastner G, Merz F et al (2007) IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: results of an ISIORT pooled analysis. Strahlenther Onkol 183:32–34PubMedCrossRefGoogle Scholar
  13. 13.
    Krengli M, Calvo FA, Sedlmayer F et al (2013) Clinical and technical characteristics of intraoperative radiotherapy. Analysis of the ISIORT-Europe database. Strahlenther Onkol 189:729–737PubMedCrossRefGoogle Scholar
  14. 14.
    Fastner G, Sedlmayer F, Merz F et al (2013) IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysis. Radiother Oncol 108:279–286PubMedCrossRefGoogle Scholar
  15. 15.
    Kaplan EL, Meier P (1958) Nonparametric-Estimation from Incomplete Observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  16. 16.
    Voduc KD, Cheang MC, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691PubMedCrossRefGoogle Scholar
  17. 17.
    Millar EK, Graham PH, O’Toole SA et al (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27:4701–4708PubMedCrossRefGoogle Scholar
  18. 18.
    Elsawaf Z, Sinn HP, Rom J et al (2013) Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. Breast 22:986–992PubMedCrossRefGoogle Scholar
  19. 19.
    Luporsi E, Andre F, Spyratos F et al (2012) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132:895–915PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Vaidya JS, Baldassarre G, Massarut S (2009) Beneficial effects of intraoperative radiotherapy on tumor microenvironment could improve outcomes (Int J Radiat Oncol Biol Phys 2008;72:1575–1581). Int J Radiat Oncol Biol Phys 74:976PubMedCrossRefGoogle Scholar
  21. 21.
    Belletti B, Vaidya JS, D’Andrea S et al (2008) Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res 14:1325–1332PubMedCrossRefGoogle Scholar
  22. 22.
    Herskind C, Griebel J, Kraus-Tiefenbacher U et al (2008) Sphere of equivalence—a novel target volume concept for intraoperative radiotherapy using low-energy X rays. Int J Radiat Oncol Biol Phys 72:1575–1581PubMedCrossRefGoogle Scholar
  23. 23.
    Pogoda K, Niwinska A, Murawska M et al (2013) Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol 30:388PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Montagna E, Bagnardi V, Rotmensz N et al (2012) Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 23:324–331PubMedCrossRefGoogle Scholar
  25. 25.
    Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence afte breast-conserving therapy. J Clin Oncol 26:2373–2378PubMedCrossRefGoogle Scholar
  26. 26.
    Moran MS (2015) Radiation therapy in the locoregional treatment of triple-negative breast cancer. Lancet Oncol 16:e113–e122CrossRefGoogle Scholar
  27. 27.
    Zaky SS, Lund M, May KA et al (2011) The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy. Ann Surg Oncol 18:2858–2865PubMedCrossRefGoogle Scholar
  28. 28.
    Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Gerd Fastner
    • 1
    Email author
  • Cornelia Hauser-Kronberger
    • 4
  • Angelika Moder
    • 5
  • Roland Reitsamer
    • 2
    • 3
  • Franz Zehentmayr
    • 1
  • Peter Kopp
    • 1
  • Christoph Fussl
    • 1
  • Thorsten Fischer
    • 2
    • 3
  • Heinrich Deutschmann
    • 1
    • 6
  • Felix Sedlmayer
    • 1
  1. 1.Department of Radiotherapy and Radio-OncologyLandeskrankenhaus, Paracelsus Medical UniversitySalzburgAustria
  2. 2.Department of Special GynecologyLandeskrankenhaus, Paracelsus Medical UniversitySalzburgAustria
  3. 3.Department of GynecologyLandeskrankenhaus, Paracelsus Medical UniversitySalzburgAustria
  4. 4.Department of PathologyLandeskrankenhaus, Paracelsus Medical UniversitySalzburgAustria
  5. 5.Institute of Inborn Errors in MetabolismLandeskrankenhaus, Paracelsus Medical UniversitySalzburgAustria
  6. 6.Institute for Research and Development of Advanced Radiation Technologies (radART)Paracelsus Medical UniversitySalzburgAustria

Personalised recommendations